CV 205-502(Sandoz Ltd,瑞士),一种八氢苯喹啉,是一种新的非麦角类长效多巴胺能激动剂。本药能抑制各种动物模型的催乳素(PRL)分泌,作用较溴隐亭强35倍,与硫丙麦角林(pergolide)相似,而且作用时间长。本文报道 CV 205-502在高 PRL 血症患者中的首次双肖试验结果。高 PRL 血症妇女24例中,21例已停用溴隐亭1个月以上,3例未用多巴胺激动剂。内分泌检查除甲 CV 205-502 (Sandoz Ltd, Switzerland), a octatudine, is a new non-ergot class of long-acting dopaminergic agonist. The drug can inhibit the prolactin (PRL) secretion of various animal models, the role of Bromocriptine 35 times stronger, and sulfur pergolide (pergolide) similar, and the role of a long time. This paper reports the results of the first double-shank trial of CV 205-502 in patients with high PRL. Of the 24 patients with high PRL hyperlipidemia, 21 had bromocriptine disabled for more than 1 month and 3 had no dopamine agonist. Endocrine examination in addition to a